Foundayo vs Wegovy Pill: Which Oral GLP-1 Is Better?

Wegovy Pill wins on raw efficacy. In the OASIS-1 trial, oral semaglutide 50mg produced 15.1% weight loss (ITT) and 16.6% among completers over 68 weeks. That's remarkably close to injectable Wegovy — a major achievement for a pill with only ~1% bioavailability.

Foundayo delivers meaningful but lower weight loss. In ATTAIN-1, orforglipron at the highest approved dose (17.2mg) showed 11.2% (ITT) to 12.4% (completers) over 72 weeks. That's roughly 27 lbs on average — clinically significant, but about 4 percentage points behind the Wegovy pill.

Why the gap? Despite Foundayo's far superior oral bioavailability (30–40% vs ~1%), semaglutide is a more potent GLP-1 agonist molecule. Novo Nordisk compensates for poor absorption by using a high 50mg dose with the SNAC absorption enhancer.

Context matters: This is the first time two oral GLP-1 weight loss drugs can be compared. Both are far more effective than Rybelsus (4–5% weight loss), which was the only oral GLP-1 available before 2025.

Foundayo wins decisively on convenience — and this matters more than most people realize.

Foundayo's routine: Take one pill. Any time of day. With food, without food, with coffee, with water — doesn't matter. That's it.

Wegovy Pill's routine:

• Wake up (or set an alarm 30 minutes before you want to eat)
• Take the pill on a completely empty stomach
• Use no more than 4 oz of plain water to swallow it
• Wait at least 30 minutes before eating, drinking anything else, or taking other medications

Who does this hurt most?

• Shift workers: If your schedule rotates, maintaining a strict morning fasting routine is nearly impossible
• Travelers: Time zone changes disrupt the fasting window
• People on morning medications: You can't take other pills during the 30-min wait
• Busy parents: 30 quiet minutes before breakfast isn't always available

Long-term compliance: Weight loss medications only work if you take them consistently for years. A simpler routine means better adherence, and better adherence means better real-world results — even if the clinical trial numbers are lower.

At first glance, both pills are priced competitively:

• Foundayo: $149/mo (starting dose) → $249/mo (mid dose) → $349/mo (max dose) via LillyDirect
• Wegovy Pill: $149/mo (1.5mg, 4mg) → $199/mo (8mg) → $299/mo (effective weight-loss doses) via Novo Nordisk pharmacy programs

The fine print: Wegovy Pill's $149/mo price only applies at lower titration doses (1.5mg and 4mg). At the 50mg dose where you get the 16.6% weight loss, the cost rises to approximately $299/mo. Similarly, Foundayo at the max 17.2mg dose costs $349/mo.

With manufacturer savings cards: Both drop to ~$25/month for commercially insured patients.

Medicare: Foundayo is estimated to be covered at ~$50/mo starting July 2026 under new anti-obesity medication provisions. Wegovy pill coverage under Medicare varies by plan.

Bottom line on cost: At effective weight-loss doses, Foundayo ($349) is slightly more expensive than Wegovy Pill ($299). At starting doses, they're identical ($149). Cost alone shouldn't drive the decision.

Both pills cause typical GLP-1 gastrointestinal side effects. Neither requires injections, so there are no injection-site reactions.

Foundayo (ATTAIN-1, 36mg trial dose):

• Nausea: 33.7%
• Constipation: 25.4%
• Diarrhea: 23.1%
• Vomiting: 24.0%
• Discontinuation due to AEs: 10.3%

Wegovy Pill (OASIS-1, 50mg):

• Nausea: ~31%
• Diarrhea: ~18%
• Vomiting: ~21%
• Constipation: ~14%
• Discontinuation due to AEs: ~7%

Wegovy Pill has a slightly milder GI profile in trials, with lower rates of constipation (14% vs 25.4%) and diarrhea (18% vs 23.1%). However, these are cross-trial comparisons — patient populations and study designs differed. Real-world side effect rates may vary from clinical trial results.

Note: Foundayo side effect data comes from the 36mg trial dose, which is higher than any approved dose (max approved: 17.2mg). Rates at approved doses may be lower in practice.

Semaglutide has a major cardiovascular win — but it came from the injection.

The SELECT trial (2023) demonstrated that semaglutide 2.4mg injection reduced major adverse cardiovascular events (MACE) by 20% in patients with established cardiovascular disease and overweight/obesity. This was a landmark finding that expanded the argument for GLP-1 treatment beyond weight loss alone.

But SELECT used injectable Wegovy, not the pill. There is no completed CV outcomes trial for oral semaglutide 50mg specifically. While it's reasonable to expect some cardiovascular benefit from the same molecule in oral form, the magnitude of the effect may differ given the different pharmacokinetics.

Foundayo has no CV outcomes trial. Orforglipron is a different molecule entirely, and no large cardiovascular outcomes study has been completed. Standard safety monitoring in ATTAIN trials did not raise cardiovascular red flags, but the absence of a dedicated CV outcomes trial means we can't make claims about cardioprotection.

For patients with established cardiovascular disease: The semaglutide platform (including injectable Wegovy) has the strongest evidence. Whether the oral pill confers the same benefit is an extrapolation your cardiologist should weigh in on.

Choose Foundayo if:

• Convenience is your top priority — you want zero restrictions on when and how you take your pill
• You're a shift worker, frequent traveler, or have an unpredictable morning routine
• You take other morning medications and don't want a 30-min gap
• You're already in the Lilly ecosystem (e.g., switching from Zepbound)
• You value long-term adherence over maximum short-term efficacy

Choose Wegovy Pill if:

• Maximum weight loss is your primary goal and you want the stronger pill
• You can reliably commit to the 30-minute fasting routine every morning
• Your doctor recommends semaglutide specifically (e.g., for cardiovascular risk reduction)
• You want the extrapolated cardiovascular benefit from the semaglutide platform
• Your insurance covers Wegovy but not Foundayo